Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability
Scripps Research Institute · Boston Children's Hospital · +5 more institutions
Abstract
During the COVID-19 pandemic, Pfizer-BioNTech and Moderna successfully developed nucleoside-modified mRNA lipid nanoparticle (LNP) vaccines. SARS-CoV-2 spike protein expressed by those vaccines are identical in amino acid sequence, but several key components are distinct. Here, we compared the effect of ionizable lipids, untranslated regions (UTRs), and nucleotide composition of the two vaccines, focusing on mRNA delivery, antibody generation, and long-term stability. We found that the ionizable lipid, SM-102, in Moderna's vaccine performs better than ALC-0315 in Pfizer-BioNTech's vaccine for intramuscular delivery of mRNA and antibody production in mice and long-term stability at 4 °C. Moreover,…
Citation impact
- FWCI
- 29.36
- Percentile
- 100%
- References
- 76
Authors
10- LZLizhou ZhangCorresponding
Scripps Research Institute, Boston Children's Hospital, Harvard University, Boston Children's Museum
- KRKunal R. More
The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology
- AOAmrita Ojha
The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology
- CBCody B. Jackson
Boston Children's Hospital, Harvard University, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology
- BDBrian D. Quinlan
The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology
Topics & keywords
- Messenger RNA
- Untranslated region
- Virology
- Nucleoside
- Nucleotide
- Antibody
- Biology
- Chemistry
- Good health and well-being